This Article Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sissons, G. R. J. Articles by Penney, M. D. Search for Related Content PubMed PubMed Citation Articles by Sissons, G. R. J. Articles by Penney, M. D.

Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?

G. R. J. Sissons, MRCP, FRCR R. Clements, MA, FRCS, FRCR W. B. Peeling, MA, FRCS ^* and M. D. Penney, MD, MRCPath

Department of Radiology, Royal Gwent Hospital, Newport, Gwent NP9 2UB, UK ^* Department of Urology, Royal Gwent Hospital, Newport, Gwent NP9 2UB, UK Department of Chemical Pathology, Royal Gwent Hospital, Newport, Gwent NP9 2UB, UK

Bone scintigraphy is the most sensitive imaging technique for the initial detection of bone metastases and is widely used in the staging of prostatic cancer. This study was performed to assess whether the development of further bone metastases can be detected by serial measurements of the serum glycoprotein prostate-specific antigen (PSA) as an alternative to follow-up scintigraphy. The bone scintigrams and PSA levels of 101 patients with metastatic prostate cancer entered into two therapeutic trials have been reviewed. Serial results of both investigations were available in 59 cases. In three cases new bone deposits were observed without a corresponding rise in PSA. In two other cases the scintigrams were considered to be suspicious of progression with no change in PSA levels; however, further follow-up indicated that these changes were not due to metastases. In 13 cases PSA levels were rising in advance of new deposits on the scintigrams. In the remaining 41 cases the PSA levels and scintigraphic findings paralleled each other. We conclude that serial estimation of PSA levels is a simpler marker for disease progression than bone scintigraphy in metastatic prostatic cancer, but that neither technique in isolation gives complete accuracy.

Key Words: Prostate cancer • Scintigraphy • Prostate-specific antigen

Received for publication November 21, 1991. Revision received April 16, 1992. Accepted for publication April 28, 1992.